市场调查报告书
商品编码
1494878
到 2030 年药用玻璃安瓿市场预测:按产品类型、类型、产能、应用、最终用户和地区进行的全球分析Pharmaceutical Glass Ampoules Market Forecasts to 2030 - Global Analysis By Product Type, Type, Capacity, Application, End User and By Geography |
根据 Stratistics MRC 的数据,2024 年全球药用玻璃安瓿市场规模为 148 亿美元,预计在预测期内复合年增长率为 8.9%,到 2030 年将达到 247 亿美元。
药用玻璃安瓿是由玻璃製成的密封管瓶,用于封装和储存液体药物,特别是注射用药物。这些安瓿通常由优质硼硅酸玻璃製成,具有出色的耐化学性和热稳定性,确保封装药品的纯度和稳定性。玻璃材料可防止药物与容器的相互作用并保持药物的功效和安全性。药用玻璃安瓿广泛应用于医院和临床环境,对于安全有效地传递疫苗、注射和其他关键药物至关重要。
根据 CNN 和 OWID 报导,截至 2023 年 3 月 20 日,全球已接种了约 130 亿剂 COVID-19 疫苗,其中美国接种了约 6.72 亿剂。
药品需求增加
药品中单剂量包装的成长趋势与玻璃安瓿的优势完全一致。单剂量包装可最大限度地降低药物污染风险并确保剂量准确。玻璃安瓿为这个不断成长的市场提供了一个方便、安全的解决方案。此外,许多药品,特别是那些源自生物技术或含有敏感成分的药品,需要包装提供出色的保护,以防止水分、空气和劣化等因素的影响。具有优异阻隔性能和化学惰性的玻璃安瓿是这种敏感药品的理想选择,并正在推动市场成长。
製造成本高
製造玻璃安瓿需要复杂的製程和高品质的硼硅酸玻璃,而且价格昂贵。对纯度和安全性的严格监管要求进一步加剧了这些成本,这需要先进的技术和严格的品管措施。因此,整体製造成本明显较高。小型製药公司,尤其是新兴市场的小型製药公司,可能难以满足这些高成本,这限制了注射药物的生产和分销并阻碍了市场成长。
环保考量
对永续性的日益关注为药用玻璃安瓿市场创造了机会。玻璃是一种可回收材料,使其成为比某些塑胶包装更环保的选择。随着消费者和医疗保健提供者的环保意识越来越强,对玻璃安瓿等永续包装解决方案的需求可能会增加。因此,玻璃安瓿提供了一种展示对环境责任的承诺的方式,并有可能吸引具有环保意识的客户。
自动化可能性有限
玻璃安瓿製造涉及复杂的流程,难以完全自动化,并且严重依赖技术纯熟劳工进行品管和封装等精密操作。此外,缺乏自动化会减慢生产速度,阻碍满足不断增长的药品需求的能力,特别是在流行病和健康危机等激增期间。这些低效率可能导致供应链中断和基本药物交付延迟,从而影响医疗保健提供者和患者。
COVID-19 的影响
疫苗和注射药物需求的激增导致药用玻璃安瓿产量增加,以支持大规模免疫宣传活动和治疗行动。然而,全球供应链和製造业务的中断最初成为一个问题,导致供不应求。此外,对疫苗分发和储存的需求不断增加,凸显了可靠、高品质玻璃安瓿的重要性。
预计直管安瓿细分市场在预测期间规模最大
随着对更安全、更方便的包装的需求不断增加,直管安瓿预计在预测期内将以最高销售量成长。对于希望在药用玻璃安瓿市场上实现产品差异化的製造商来说,直管安瓿代表着竞争优势。其独特的设计和安全性可以吸引寻求创新解决方案的医疗提供者和製药公司。
中性玻璃安瓿细分市场预计在预测期内复合年增长率最高
中性玻璃安瓿具有优异的耐化学性,使其适合储存多种药物配方,包括酸性、碱性和中性化合物。这种多功能性使製药公司能够在各种配方中使用中性玻璃安瓿,从而扩大市场覆盖范围。
由于慢性病增加、注射药物需求增加以及对安全可靠的包装解决方案的需求有助于市场扩张等因素,预计北美将在预测期内占据最大的市场占有率。此外,玻璃製造流程的技术进步、严格的监管标准以及主要市场参与企业的存在进一步刺激了市场成长。
随着中国建立製药业的标准框架,预计亚太地区在预测期内将保持最高的复合年增长率。国家越来越注重药品包装材料在药品储存过程中的稳定性以及包装在使用过程中的安全性。由于玻璃包装的耐用性、非反应性、透明度、环境相容性和多功能性,製药公司越来越多地转向玻璃包装。此外,由于医疗保健系统投资增加、研发增加以及药品成本增加,管瓶的需求量很大。
According to Stratistics MRC, the Global Pharmaceutical Glass Ampoules Market is accounted for $14.8 billion in 2024 and is expected to reach $24.7 billion by 2030 growing at a CAGR of 8.9% during the forecast period. Pharmaceutical glass ampoules are small, sealed vials made from glass, used to contain and preserve liquid medications, especially for injectable purposes. These ampoules are typically made from high-quality borosilicate glass, which offers excellent chemical resistance and thermal stability, ensuring the purity and stability of the contained pharmaceutical products. The glass material prevents interaction between the drug and the container, maintaining the efficacy and safety of the medication. This is widely used in hospitals and clinical settings, pharmaceutical glass ampoules are crucial for delivering vaccines, injectable drugs, and other critical medications safely and effectively.
According to CNN and OWID, as of March 20, 2023, about 13 billion COVID-19 vaccine doses had been administered globally, with the United States accounting for almost 672 million.
Rising Demand for Pharmaceuticals
The growing trend towards single-dose packaging in pharmaceuticals aligns perfectly with the strengths of glass ampoules. Single-dose packaging minimizes the risk of medication contamination and ensures precise dosage administration. Glass ampoules provide a convenient and safe solution for this growing market segment. Moreover many medications, particularly those derived from biotechnology or containing delicate components, require packaging that offers superior protection against factors like moisture, air, and light degradation. Glass ampoules, with their excellent barrier properties and chemical inertness, are ideal for this sensitive drug drives the growth of the market.
High cost of production
Manufacturing glass ampoules involves complex processes and high-quality borosilicate glass, which can be expensive. These costs are further compounded by stringent regulatory requirements for purity and safety, necessitating advanced technology and rigorous quality control measures. As a result, the overall production costs are significantly high. Smaller pharmaceutical companies, particularly in developing regions, might struggle to afford these higher costs, limiting their ability to produce or distribute injectable medications effectively hampers the growth of the market.
Eco-friendly considerations
The growing focus on sustainability presents an opportunity for the pharmaceutical glass ampoule market. Glass is a recyclable material, making it an eco-friendly alternative compared to some plastic packaging options. As consumers and healthcare institutions become more environmentally conscious, the demand for sustainable packaging solutions like glass ampoules could rise. Thus glass ampoules can be a way to showcase a commitment to environmental responsibility, potentially attracting environmentally conscious customers.
Limited automation potential
Manufacturing glass ampoules involves intricate processes that are difficult to fully automate, relying heavily on skilled labor for precision tasks like quality control and sealing. Additionally, the lack of automation leads to slower production rates, hindering the ability to meet the growing demand for pharmaceutical products, especially during surges such as during pandemics or health crises. This inefficiency can result in supply chain disruptions and delays in the delivery of essential medications, impacting healthcare providers and patients.
Covid-19 Impact
The surge in demand for vaccines and injectable medications led to increased production of pharmaceutical glass ampoules to accommodate mass vaccination campaigns and treatment efforts. However, disruptions in global supply chains and manufacturing operations initially posed challenges, resulting in supply shortages. Additionally, heightened focus on vaccine distribution and storage requirements emphasized the importance of reliable and high-quality glass ampoules.
The straight-stem ampoules segment is expected to be the largest during the forecast period
The straight-stem ampoules is expected to be the largest during the forecast period as the demand for safer and more user-friendly packaging grows, straight-stem ampoules offer a competitive advantage for manufacturers looking to differentiate their products in the Pharmaceutical Glass Ampoules market. Their unique design and safety features can attract healthcare providers and pharmaceutical companies seeking innovative solutions.
The neutral glass ampoules segment is expected to have the highest CAGR during the forecast period
The neutral glass ampoules segment is expected to have the highest CAGR during the forecast period owing to the chemical resistance of neutral glass makes it suitable for storing a diverse range of pharmaceutical formulations, including acidic, basic, and neutral compounds. This versatility allows pharmaceutical companies to use neutral glass ampoules for various drug formulations, expanding their market applicability.
North America is projected to hold the largest market share during the forecast period owing to factors such as the increasing prevalence of chronic diseases, rising demand for injectable medications, and the need for secure and reliable packaging solutions contribute to market expansion. Additionally, technological advancements in glass manufacturing processes, stringent regulatory standards, and the presence of key market players further stimulate market growth.
Asia Pacific is projected to hold the highest CAGR over the forecast period as China has established a standard framework for the pharmaceutical industry. The country is increasingly focusing on the stability of pharmaceutical packaging materials during drug storage and the safety of the packaging when used. Pharmaceutical companies increasingly use glass packaging because of its durability, non-reactivity, transparency, eco-friendliness, and versatility. Additionally, glass vials are in high demand due to increasing investment and R&D in healthcare systems and rising drug spending.
Key players in the market
Some of the key players in Pharmaceutical Glass Ampoules market include AAPL Solutions Pvt. Ltd, Accu-Glass LLC, Adit Containers Private Limited, Agrado SA, Birgimefar Group, BOROSIL, CORNING INCORPORATED, Gerresheimer AG, J. Penner Corporation, Kapoor Glass India Pvt. Lt, NIPRO Corporation, Schott AG, SGD SA (SGD Pharma), Shandong Pharmaceutical Glass Co. Ltd, Sm Pack SpA, Stevanato Group SPA, Stoelzle Oberglas GmbH and Zhengchuan Pharmaceutical Packaging
In April 2024, SCHOTT launches pilot projects on glass-ceramics and specialty glass for a more circular economy. The circular economy a joint challenge for policymakers and the specialty glass industry
In March 2024, Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fill(R) Syringes and Cartridges, the facility started commercial production in Q4 2023 and houses advanced production lines developed by Stevanato Group for the production of EZ-fill(R) pre-sterilized syringes
In March 2024, Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters' Option to Purchase Additional Ordinary Shares. The total gross proceeds from the Offering, before deducting underwriting discounts and commissions
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.